
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00.
Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share.

Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00.
Shares of Apellis Pharmaceuticals are trading down 2.3% over the last 24 hours, at $43.40 per share.